C-mo Medical Solutions Achieves ISO 13485 Certification for AI-Powered Cough Monitoring Technology
核心洞察
C-mo Medical Solutions (搜索) has received ISO 13485:2016 certification, demonstrating compliance with stringent regulatory requirements for medical device design, development, manufacturing, and servicing.
The company's AI-powered biosensor and digital platform provides comprehensive, objective, and privacy-preserving cough (搜索) monitoring solutions for pharmaceutical companies, CROs, researchers, and healthcare providers.
This certification positions C-mo to launch its technology into the clinical trials market in the coming months, supporting pharmaceutical partners with real-world cough (搜索) data.
C-mo Medical Solutions (搜索), a leading provider of next-generation cough (搜索)-monitoring technology, has received ISO 13485:2016 certification, marking a significant regulatory milestone as the company prepares to enter the clinical trials market. The internationally recognized certification demonstrates that the Portugal-based MedTech company meets stringent regulatory requirements for the design, development, manufacturing, distribution, and servicing of its medical devices.
"ISO 13485 certification is a foundational milestone for us," said Diogo Tecelão, chief executive officer of C-mo Medical Solutions (搜索). "It reflects the high standards we've set in quality and compliance – and is a step forward in our mission to supporting clinical trials and medical practice with our high-quality, regulatory-grade cough (搜索) monitoring solutions."
AI-Powered Cough Assessment Technology
C-mo's flagship technology provides a comprehensive, objective, and privacy-preserving solution for cough (搜索) monitoring, enabling pharmaceutical companies, contract research organizations (CROs), researchers, and healthcare providers to track and analyze the multiple dimensions of cough with clinical precision. The company's AI-powered biosensor and digital platform delivers what the company describes as the most comprehensive assessment of cough, enabling precise and clinically meaningful characterization of a patient's respiratory health.
The technology stands out for its privacy-preserving capabilities, representing the first solution to ensure privacy by not recording conversations while providing unobtrusive, long-term monitoring with exceptional reliability. This feature addresses a critical concern in respiratory monitoring applications where patient privacy is paramount.
Market Readiness and Industry Impact
The certification comes as C-mo prepares to launch its technology into the clinical trials market in the coming months. Chris Bergstrom, chairman of the board at C-mo Medical Solutions (搜索), emphasized the strategic importance of this achievement: "ISO 13485 certification is a key enabler for companies operating at the intersection of AI, technology, and clinical research. This achievement underscores C-mo's readiness to serve regulated markets and support pharmaceutical partners with real-world cough (搜索) data that sets a new benchmark for quality and insight – meeting the growing demand across the industry."
The certification aligns with the company's broader goal to become the reference in cough (搜索) assessment, bringing digital precision to respiratory endpoints and transforming how cough is understood, measured, and managed in clinical settings.
Clinical Applications and Biomarker Potential
C-mo Medical Solutions (搜索) positions itself as addressing unmet needs in the monitoring and management of chronic cough (搜索) by unlocking the clinical value of cough (搜索) as a biomarker. The company's mission focuses on developing innovative solutions that improve patient care through advanced respiratory health monitoring capabilities.
The technology's applications span both clinical trials and medical practice, offering pharmaceutical partners and healthcare providers a tool for objective cough (搜索) assessment that could enhance respiratory endpoint evaluation in drug development and patient management.
Investment and Market Position
The company has secured backing from leading investors including Boehringer Ingelberg Venture Fund, High-Tech Gründerfonds (搜索), Novalis (搜索), and Portugal Ventures (搜索), indicating strong industry confidence in the technology's potential impact on respiratory health monitoring and clinical research applications.